March 4, 2021 -- Biogen is planning to build a new manufacturing facility spanning 175,000 sq ft at its base in Research Triangle Park, NC, to support development of its pipeline of gene therapies.
Biogen currently employs a total of approximately 1,900 staff at Research Triangle Park locations and plans to fill 90 new positions. The new facility, which is being created with funding of $200 million, is expected to be up and running by 2023.
Biogen's gene therapy pipeline assets include BIIB111 (timrepigene emparvovec), which is in phase III development for the rare retinal genetic disease choroideremia, and BIIB112 (formerly called NSR-RPGR), which is in phase II for X-linked retinitis pigmentosa.
Copyright © 2021 scienceboard.net